Investors seeking stability in their investments should consider Alcon, according to JPMorgan. The bank recently upgraded the eye care company’s stock from neutral to overweight, while also increasing its price target from $79.80 to $89.30 per share. This forecast suggests a potential 11% increase from the previous day’s closing price of $80.24. JPMorgan’s decision comes after Alcon reported better-than-expected second-quarter results and raised its full-year earnings guidance. Although the stock only experienced a slight increase following the report, analyst David Adlington believes that the company has multiple growth opportunities in its implantable segment and overall higher equipment volume. Adlington stated, “The positive earnings’ momentum looks set to continue.” In 2023, Alcon’s stock has already gained over 17%.

Categorized in: